0.0 0.0 Change from baseline (adjusted mean*) 0.0 -0.0 -0.0 Difference from placebo + sulfonylurea (adjusted mean*) 00% Confidence Interval -0.0† (-0.0, -0.0) -0.0† (-0.0, -0.0) Fasting Plasma Glucose (mg/dL) N=000 N=000 N=000 Baseline (mean) 000 000 000 Change from baseline (adjusted mean*) 0 -00 -00 Difference from placebo + sulfonylurea (adjusted mean*) 00% Confidence Interval -00† (-00, -00) -00† (-00, -00) In the second trial, 000 patients were randomized to receive 00 mg or 00 mg of pioglitazone hydrochloride once daily for 00 weeks in addition to their current sulfonylurea regimen. The mean reduction from baseline at Week 00 in HbA0c was 0.0% for the 00 mg dose and 0.0% for the 00 mg dose (see Table 00). The mean reduction from baseline at Week 00 in FPG was 00 mg/dL for the 00 mg dose and 00 mg/dL for the 00 mg dose. The therapeutic effect of pioglitazone hydrochloride in combination with 